{"id":132298,"date":"2022-08-03T09:05:33","date_gmt":"2022-08-03T13:05:33","guid":{"rendered":"https:\/\/44.250.171.167\/?p=132298"},"modified":"2022-10-06T04:53:55","modified_gmt":"2022-10-06T08:53:55","slug":"dr-lal-pathlabs-ltd-q1-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q1-fy23-earnings-conference-call-insights\/","title":{"rendered":"Dr Lal PathLabs Ltd Q1 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Dr Lal PathLabs Ltd Q1 FY23 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/GyHJJGLWdjg?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Dr Lal PathLabs Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/LALPATHLAB\/\">LALPATHLAB<\/a>) Q1 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Management Update:<\/strong><\/p>\n<ul>\n<li>LALPATHLAB said it clocked the highest quarterly non-COVID revenue of INR482 crore, a growth of 25% YoYs. Additionally, COVID revenue significantly declined by 91% from INR221 crore to INR21 crore in 1Q23.<\/li>\n<\/ul>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Pooja Bhatia from Morgan Stanley asked if the company is holding on to FY23 guidance of mid-teen revenue growth given in 4Q22 and the volume\/value split. Om Prakash MD replied that the company\u2019s best estimate is to maintain that, but it\u2019s difficult right now to put a number. LALPATHLAB is confident of having a pre-COVID growth rate of 13-15% in non-COVID category.<\/li>\n<\/ul>\n<ul>\n<li>Pooja Bhatia with Morgan Stanley also enquired that on the M&amp;A front, what assets interest the company. Om Prakash MD replied that there is nothing to share right now. But the team is focused on making the suburban asset integrate and work well. But right now, the company will have a wait and watch strategy.<\/li>\n<\/ul>\n<ul>\n<li>Pooja Bhatia from Morgan Stanley asked about the roadmap to improve margins in suburban from 12% to 30%. Om Prakash MD replied that it believes if the company focus on topline aggressively in suburban, it should be able to improve margins as the business is concentrated in Mumbai and potential is high.<\/li>\n<\/ul>\n<ul>\n<li>Sriraam Rathi of BNP Paribas enquired how much of revenue is coming from franchises. Bharath Uppiliappan CEO answered that 40% plus is franchisee business. But there has not been a sharp increase in fees to collection centers, it has been as per normal trends. Also, the contribution of a franchisee business to the total business is on the rise.<\/li>\n<\/ul>\n<ul>\n<li>Sriraam Rathi of BNP Paribas asked about other expenses being higher in 1Q23 and if the company expects the INR105 crore run rate to continue. Ved Prakash CFO replied that comparing 4Q22 to 1Q23, there are investments the company has made on IT digital side and the other is on marketing.<\/li>\n<\/ul>\n<ul>\n<li>Shyam Srinivasan from Goldman Sachs asked about non-COVID sales, the split between volume and price. Bharath Uppiliappan CEO said volume growth is about 12.5%, 13% give or take and rest is mix impact on pricing. So a price impact of 2% odd. It is not a price increase, but a mix impact.<\/li>\n<\/ul>\n<ul>\n<li>Prakash Kapadia from Anived Portfolio asked how the company is managing attrition if any due to increased competition. Bharath Uppiliappan CEO answered that on attrition there is nothing substantial. Front line attrition remains at previous rate.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q1 FY23 Earnings Concall Management Update: LALPATHLAB said it clocked the highest quarterly non-COVID revenue of INR482 crore, a growth of 25% YoYs. Additionally, COVID revenue significantly declined by 91% from INR221 crore to INR21 crore in 1Q23. Q&amp;A Highlights: Pooja Bhatia from Morgan Stanley asked if [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Dr Lal PathLabs Ltd Q1 FY23 Earnings Conference Call Insights #LALPATHLAB #Q1 #FY23 #earnings","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[8665,8157],"class_list":["post-132298","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-diagnostics","tag-healthcare"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":129608,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":132298,"position":0},"title":"Dr Lal PathLabs Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 18, 2022","format":false,"excerpt":"https:\/\/youtu.be\/XGfFd6kLFCE Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY22 Earnings Concall Management Update: LALPATHLAB said it saw significant shift towards direct-to-home business, with home collections now contributing nearly 12%, which used to be in the range of 5-6% during pre-COVID days. Also the company saw bundled packages continuing\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":140051,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":132298,"position":1},"title":"Dr Lal PathLabs Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"February 3, 2023","format":false,"excerpt":"Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q3 FY23 Earnings Concall Q&A Highlights: [00:12:28] Dheeresh Pathak from WhiteOak asked about the revenue and EBITDA for Suburban for 3Q23. C. A. Ved Prakash CFO said Suburban had revenue of INR37 crores, with INR35 crores from non-COVID and the rest from\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":136294,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":132298,"position":2},"title":"Dr Lal PathLabs Ltd Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 10, 2022","format":false,"excerpt":"https:\/\/youtu.be\/lAaNZKEvjOc Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q2 FY23 Earnings Concall Q&A Highlights: [00:16:43] Rahul Agarwal with Incred Capital enquired about 2Q23 performance according to the company\u2019s expectations. Arvind Lal EC said the company\u2019s opinion is that the performance is slightly in line with what it was doing\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":139887,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-limited-q3-fy23-net-profit-down-by-8\/","url_meta":{"origin":132298,"position":3},"title":"Dr. Lal PathLabs Limited Q3 FY23; Net Profit  Down By 8%","author":"Hardik Bhandare","date":"February 2, 2023","format":false,"excerpt":"Dr. Lal PathLabs Limited (NSE: LALPATHLAB) reported a Revenue from Operations of \u20b9489.4 Crores, a decline of 1.5% from the previous year. The Consolidated Net Profit for the business also decreased by 8% year over year, to \u20b953.6 Crore from \u20b958.2 Crore. Earnings per Share is \u20b96.35 for this quarter.","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":132319,"url":"https:\/\/alphastreet.com\/india\/earnings-infographic-dr-lal-pathlabs-q1-2023-revenue-and-profit-decline\/","url_meta":{"origin":132298,"position":4},"title":"Earnings Infographic: Dr. Lal PathLabs Q1 2023 revenue and profit decline","author":"Manoj_Nair","date":"August 3, 2022","format":false,"excerpt":"Dr. Lal PathLabs Ltd (NSE: LALPATHLAB), a leading provider of diagnostic and related healthcare services, has reported lower revenues and earnings for the first quarter of 2023. The company also announced an interim dividend of \u20b96 per share. First-quarter revenues dropped 17% year-over-year to \u20b9502.7 crores, hurt by a sharp\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/08\/Dr.-Lal-PathLabs-Q1-2023-earnings-infographic.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":127290,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":132298,"position":5},"title":"Dr Lal PathLabs Ltd Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 11, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=q_lILVipT-E Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q3 FY22 Earnings Concall Management Update: The company is enhancing access of its services by strengthening omni-channel approach in cities and pursuing hub lab infrastructure in Tier 2 and Tier 3 towns. During 3Q22, the company successfully integrated AI in prostate\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/132298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=132298"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/132298\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=132298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=132298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=132298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}